Navigation Links
Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
Date:6/11/2008

omplishment and the inhalation-based delivery of siRNA to the respiratory system demonstrate the unique strengths of our siRNA program."

For more information on the conference please visit: http://www.beyondgenome.com/

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry that the Company believes provide Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability to deliver siRNA locally and systemically to organs including the eye, ear, kidney, lung, spinal cord and bone marrow.

Quark's lead product, PF-4523655 (RTP801i-14), completing Phase I/IIa clinical trials, is a synthetic, chemically modified, siRNA molecule to temporarily inhibit the expression of Quark's proprietary target gene RTP801. PF-4523655 is licensed to Pfizer on an exclusive worldwide basis. Quark expects its partner, Pfizer, to continue to progress PF-4523655 through Phase II clinical trials for the treatment of AMD and diabetic macular edema (DME). In addition, Quark's current clinical pipeline includes AKIi-5, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery, currently in Phase I/IIa clinical trials via systemic delivery. Based on publicly available information, Quark believes this was the first siRNA delivered systemically in a human clinical trial. The Company has licenses for AtuRNAi(TM) technology from Silence Therapeutics and additional RNAi intellectual property from Alnylam

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
2. The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
3. Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
4. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
5. Amira Pharmaceuticals Hires Industry Veteran for CFO Position
6. Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter
7. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
8. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
9. Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
10. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
11. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 21, 2014 Shimadzu Scientific Instruments introduces ... tool for the pain management and clinical markets. The ... and review by allowing users to highlight and review ... , QuantAnalytics allows analysts to filter results by group ... processing by eliminating the need to sift through analytes ...
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... 11 Genta,Incorporated (Nasdaq: GNTA ) announced ... institutional investors to sell 6 million shares,of common ... totaling,approximately $3.1 million before fees and expenses. The ... February 13, 2008, subject to the,satisfaction of customary ...
... over Same Quarter Last Year - ... - FY08 Revenue Guidance Raised - - ... MINNEAPOLIS, Feb. 11 Uroplasty, Inc. (Amex:,UPI), a medical device company ... dysfunction,today reported record net sales of $3.7 million for the third quarter ...
... This week, Summit VetPharm,identified the first instance ... Vectra 3D(TM) flea and tick product. This situation,where ... popular website targeting,pet owners, is a clear violation ... after confirming the identity of the California,veterinarian, swiftly ...
Cached Biology Technology:Genta Announces Common Stock Offering of Approximately $3.1 Million 2Genta Announces Common Stock Offering of Approximately $3.1 Million 3Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 2Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 3Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 4Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 5Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 6Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 7Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 8Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 9Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 10Summit VetPharm Addressed Veterinarian Diverted Vectra 3D(TM) 2Summit VetPharm Addressed Veterinarian Diverted Vectra 3D(TM) 3
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to inhibit ... development of skin cancers by turning on an enzyme ... cells. , Previously considered protective, SIRT6 is part of ... regulate genomic stability and prevent some of the genetic ... which can lead to cancer. This study, in the ...
(Date:10/14/2014)... October 14, 2014 – High doses of fish oil supplements, ... a common type of irregular heartbeat in which the heart ... results of the AFFORD trial led by the Montreal Heart ... College of Cardiology on October 7th. , For the ... therapy were randomly assigned to 4 grams of fish oil ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... the structure of unknown natural compounds is a slow ... but this may now change thanks to a new ... University of California, San Diego and presented at RECOMB ... in Singapore. UC San Diego researchers have devised ...
... have just confirmed what poets have known for centuries: eyes ... brain. In a new study published in the April 2008 ... Harvard researchers describe the development of gene probe eye ... detect tissue repair in the brain of living organisms using ...
... known that the left and right sides of the brain ... influence cognitive performance and social behaviour. For instance, in humans, ... processing whereas the right side is better at comprehending musical ... work in the open access journal Neural Development have pinpointed ...
Cached Biology News:UC San Diego researchers eliminate drug discovery bottleneck 2UC San Diego researchers eliminate drug discovery bottleneck 3UC San Diego researchers eliminate drug discovery bottleneck 4Harvard researchers publish MRI images of genes in action in the living brain 2Neurons hard wired to tell left from right 2
... a glycoprotein. distributed in colon and ... breast, lung and salivary gland tissues. ... MUC1 and MUC2. Epitope: Tandem ... Immunogen: MUC3 tandem repeat peptide ...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
... The 2/3D Waver Shaker combines shaking and rocking ... a 330 x 330 mm stainless steel or ... incubator and cold room operation. The platform angle ... for a vigorous with action and rotation speed ...
Biology Products: